![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1432410
¼¼°è ½Å°æ±â±â ½ÃÀå : Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ,Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)Global Neurology Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) |
¼¼°è ½Å°æ±â±â ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 144¾ï ´Þ·¯·Î ÃßÁ¤µÇ°í, 2029³â¿¡´Â 182¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, ¿¹Ãø ±â°£ Áß(2024³â-2029³â) º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 4.86%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
COVID-19ÀÇ À¯ÇàÀº Àü ¼¼°è °Ç° °ü¸® ½Ã½ºÅÛ¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡¸ç COVID-19 °¨¿° ȯÀÚ»Ó¸¸ ¾Æ´Ï¶ó ´Ù¸¥ ȯÀÚ¿¡°Ôµµ Å« ¿µÇâÀ» ¹ÌÄ¡¸ç ÀÚ¿ø °ü¸® ¹× ºñÃàÀ» À§ÇØ Ä¡·á ¹× ¼ö¼úÀÌ Ãë¼ÒµË´Ï´Ù. µÇ´Â °á°ú°¡ µÇ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 6¿ù ¼¼°èº¸°Ç±â±¸(WHO)´Â 155°³±¹ÀÌ 2020³â 5¿ù 3ÁÖ°£ ½Ç½ÃÇÑ Á¶»ç°á°ú¸¦ ¹ßÇ¥ÇßÁö¸¸, ÀÌ¿¡ µû¸£¸é ÆÄŲ½¼º´, ¾ËÃ÷ÇÏÀ̸Ӻ´, Ä¡¸Å µî °¢Á¾ ½Å°æ ÅðÇ༺ ÁúȯÀ» Æ÷ÇÔÇÑ °¢Á¾ ¸¸¼º ÁúȯÀÇ ¿¹¹æ,Ä¡·á ¼ºñ½º°¡ ÇöÀúÇÏ°Ô Áߴܵǰí ÀÖÀ¸¸ç, ¸¸¼º ÁúȯÀ» °¡Áø »ç¶÷µéÀº COVID-19¿Í °ü·ÃµÈ ÁßÁõȳª »ç¸ÁÀÇ À§ÇèÀÌ ³ô±â ¶§¹®¿¡ Å« ¿ì·Á°¡ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ 53% ±¹°¡°¡ ¼ºñ½ºÀÇ ÀϺΠ¶Ç´Â ÀüºÎ°¡ ÁߴܵǾú½À´Ï´Ù°í º¸°íÇÕ´Ï´Ù. ´Ù¾çÇÑ ½Å°æ ÁúȯÀÇ °ü¸®¿¡¼ÀÌ È¥¶õÀº ȯÀÚÀÇ »î¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. °Ô´Ù°¡ À¯ÇàÀº ½ÅÁ¦Ç° »ó½Ã¿¡µµ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ ¼ö Àִµ¥, ÀÌ´Â Á¶»çÇÑ ½ÃÀåÀÇ ¼ºÀå¿¡ ÀÖ¾î °¡Àå µÎµå·¯Áø ¿äÀÎÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 4¿ù, ¹ÙÀÌ¿ÀÁ¨Àº µ¥ÀÌÅÍ ºÐ¼®ÀÇ º¹À⼺°ú COVID-19°¡ R&D ÀÚ¿ø¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÀÌÀ¯·Î ½Äǰ ÀǾ౹(FDA)¿¡ ¾ËÃ÷ÇÏÀ̸Ӻ´ ¹× Ä¡¸Å Ä¡·áÁ¦ÀÇ ½ÅûÀ» ¿¬±â Çß½À´Ï´Ù. ¼ºñ½º°¡ Àç°³µÊ¿¡ µû¶ó Ä¡·á, ¼ö¼ú, Åë¿ø Áõ°¡·Î ½Å°æ Àåºñ ¹× ´Ù¾çÇÑ ½Å°æ ÁúȯÀÇ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ÁÙ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ¿äÀÎÀº ½Å°æÁúȯÀÇ ¹ß»ý·ü Áõ°¡, ½Å°æ±â±â¿¡ ´ëÇÑ ¹Î°£±â¾÷¿¡ ÀÇÇÑ °Å¾×ÀÇ ÅõÀÚ, ½Å°æÄ¡·á ºÐ¾ßÀÇ ¿¬±¸°³¹ß Áõ°¡ÀÔ´Ï´Ù.
»ç¶÷µé »çÀÌ¿¡¼ ½Å°æ Àå¾ÖÀÇ ºÎ´ãÀÌ Áõ°¡ÇÏ´Â °ÍÀÌ ¿¹Ãø ±â°£ µ¿¾È ½Å°æ Àåºñ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î À¯¿£ÀÌ ¹ßÇ¥ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2021³â 2¿ù¿¡´Â ¼¼°è Àα¸ÀÇ °ÅÀÇ 6¸í Áß 1¸í¿¡ ÇØ´çÇÏ´Â ¾à 10¾ï¸íÀÌ, 2020³â¿¡´Â ¾ËÃ÷ÇÏÀ̸Ӻ´À̳ª ÆÄŲ½¼º´, ³úÁ¹Áß, ´Ù¹ß¼º °æÈÁõ, °£Áú ÆíµÎÅë, ³ú ¼Õ»ó, ½Å°æ °¨¿°°ú °°Àº ½Å°æ Àå¾Ö·Î °íÅë¹Þ½À´Ï´Ù. ¶ÇÇÑ °°Àº Ãâó¿¡ µû¸£¸é 2019³â¿¡´Â 6,200¸¸¸íÀÌ ³úÇ÷°ü Áúȯ, 5,000¸¸¸íÀÌ °£Áú, 3¾ï 2,600¸¸¸íÀÌ ÆíµÎÅë, 2,400¸¸¸íÀÌ ¾ËÃ÷ÇÏÀ̸Ӻ´ ¹× ±âŸ Ä¡¸Å ¿¡ °É¸³´Ï´Ù. ÀÌ¿Í °°ÀÌ, »ç¶÷µé »çÀÌ¿¡¼ ½Å°æÁúȯÀÇ À¯º´·üÀÌ »ó½ÂÇϰí Àֱ⠶§¹®¿¡ û°¢À̳ª ½Ã°¢À» ȸº¹½ÃÄÑ, »çÁöÀÇ °á¼ÕÀ̳ª ¼±Ãµ¼º »çÁö Àå¾Ö¿¡ ±â´É Çâ»óÀ» Á¦°øÇÏ´Â ½Å°æ ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÑ´Ù, µû¶ó¼ ½ÃÀåÀÇ ¼ºÀåÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°Ô´Ù°¡, ½Å°æÇÐÀû Áúȯ°ú ±× Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ »ç¶÷µéÀÇ ÀÇ½Ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î ¼¼°èº¸°Ç±â±¸(WHO)°¡ 2022³â 4¿ù ¹ßÇ¥ÇÑ º¸°í¼ ¡°Draft Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022-2031³â)¡¹¿¡ µû¸£¸é 2031³â±îÁö 100% ±¹°¡°¡ ½Å°æÁúȯ¿¡ °üÇÑ °è¹ß Ä·ÆäÀΰú ±¤°í ÇÁ·Î±×·¥À» Àû¾îµµ Çϳª ±â´É½Ãų Àü¸ÁÀÔ´Ï´Ù. À¯¸í ±â°ü¿¡ ÀÇÇÑ ÀÌ·¯ÇÑ ´ëó°¡ ÇâÈÄ ½ÃÀåÀ» °ßÀÎÇØ ³ª°¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±×·¯³ª ÀåºñÀÇ ºñ¿ëÀÌ ºñ½Î°í »õ·Î¿î Àåºñ¿¡ ´ëÇÑ ½Äǰ ÀǾ౹ÀÇ °ËÁõ°ú ÁöħÀÌ ¾ö°ÝÇÏ´Ù´Â °ÍÀº ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ ÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
½Å°æ ÀÚ±Ø ÀåÄ¡ ºÎ¹®Àº °í·ÉÈ¿Í ¿ì¿ïÁõ, ¸¸¼º ÅëÁõ µîÀÇ »ýȰ ½À°üº´°ú ÇÔ²² ½Å°æ ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °Í, ±â¼úÀûÀ¸·Î ¼±ÁøÀûÀÎ Á¦Ç°ÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °Í µîÀÇ ¿äÀο¡¼ ¿¹Ãø ±â°£ µ¿¾È Å« ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
¶ÇÇÑ IEEE Engineering in Medicine and Biology Society°¡ 2021³â 2¿ù¿¡ ¹ßÇ¥ÇÑ ¡¸New Advances in Neurostimulation for Chronic Pain¡¹À̶ó´Â ŸÀÌÆ²ÀÇ ¿¬±¸¿¡ ÀÇÇϸé, Mainstay Medical»ç°¡ ³Ä¡¼ºÀÇ ¸¸¼º ¿äÅëÀÇ Ä¡·á¿¡ »ç¿ëÇÏ´Â ReActiv8 À̽ÄÇü ȸº¹ ½Å°æ ÀÚ±Ø ½Ã½ºÅÛÀ» ¼³°èÇÑ °ÍÀ¸·Î ¹àÇôÁ³½À´Ï´Ù. µû¶ó¼ Á¦Ç°ÀÇ Áøº¸´Â ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ Ã¤ÅÃÀ» Áõ°¡½ÃÄÑ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ ÅëÁõ °ü¸®¿¡¼ Á¦Ç° Ãâ½Ã¿Í ±â¼ú Áøº¸ Áõ°¡´Â ½Å°æ ÀÚ±Ø ÀåÄ¡ ¼ö¿ä¸¦ Áõ°¡½ÃŰ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 7¿ù MedtronicÀº Percept PC Deep Brain Stimulation(DBS) ½Ã½ºÅÛÀ» Ãâ½ÃÇß½À´Ï´Ù. BrainSense ±â¼ú°ú ÅëÇÕµÈ ÀÌ ½Ã½ºÅÛÀº ³ú ½ÅÈ£¸¦ µ¿½Ã¿¡ ĸóÇÏ¸é¼ Å¬¸®´Ð ³»¿Ü¿¡¼ Ä¡·á ÀÚ±ØÀ» Åõ¿©ÇÒ ¼ö ÀÖµµ·Ï ¸¸µé¾îÁ³½À´Ï´Ù. ÆÛ¼ÁÆ® PC´Â ÆÄŲ½¼º´, ¶³¸², ±Ù±äÀå, °£Áú ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿© Æí¾ÈÇÔÀÌ Çâ»óµÇ¾ú½À´Ï´Ù.
µû¶ó¼ Á¦Ç°ÀÇ Áøº¸¿Í Á¦Ç° Ãâ½Ã Áõ°¡´Â ¿¬±¸ ºÎ¹® ¼ö¿ä¸¦ Áõ°¡½ÃŰ°í ½ÃÀå ¼ºÀåÀ» ¹Ð¾î¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì´Â ½Å°æ ÁúȯÀÇ À¯º´·ü »ó½Â, ½Å°æ ÅðÇ༺ ÁúȯÀÇ Ä¡·á °³¹ß¿¡ °üÇÑ ´Ù¾çÇÑ ´Üü·ÎºÎÅÍÀÇ ÀÚ±Ý Á¦°ø Áõ°¡, µ¿Áö¿ª¿¡¼ÀÇ ¿¬±¸ °³¹ß Ȱµ¿ÀÇ È°¼ºÈ µîÀÇ ¿äÀο¡ ÀÇÇØ ½Å°æ ±â±â ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÆÄŲ½¼º´, ¾ËÃ÷ÇÏÀ̸Ӻ´, °£Áú, ½Å°æ±ÙÀå¾Ö µî ½Å°æÁúȯÀÇ ºÎ´ã Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, Alzheimers.orgÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é, ¹Ì±¹¿¡¼´Â 2021³â¿¡ 65¼¼ ÀÌ»óÀÇ 620¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ¾ËÃ÷ÇÏÀ̸Ӻ´ °ü·Ã Ä¡¸Å¸¦ ¾Î°í ÀÖ´Ù°í »ý°¢µË´Ï´Ù. ¶ÇÇÑ ÆÄŲ½¼Àç´ÜÀº 2020³â¿¡´Â 100¸¸ ¸í °¡±îÀÌ ¹Ì±¹ÀεéÀÌ ÆÄŲ½¼º´(PD)À» ¾Î°í ÀÖ´Ù°í ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù. ÀÌ ÀÚ·á¿¡ µû¸£¸é ¸Å³â 60,000 ¸íÀÇ ¹Ì±¹ÀÎÀÌ ÆÄŲ½¼ º´À¸·Î Áø´ÜµË´Ï´Ù. ¸¶Âù°¡Áö·Î ij³ª´Ù Á¤ºÎ Åë°è º¸°í¼¿¡ µû¸£¸é 2021³â 7¿ù ÇöÀç ij³ª´Ù Àα¸ÀÇ ¾à 18.5%°¡ 65¼¼ ÀÌ»óÀ̸ç 2020³â 7¿ùÀÇ 17.5%¿¡¼ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ »ç¶÷µé »çÀÌ¿¡¼ ½Å°æÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ Á¶±âÁø´Ü°ú Á¶±âÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ½Å°æ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ ³ëÀÎ Àα¸ Áõ°¡¿Í ½Å°æ Áø´Ü ¹× Ä¡·á¸¦À§ÇÑ °ß°íÇÑ °Ç° °ü¸® ÀÎÇÁ¶óÀÇ Á¸Àç´Â ¿¹Ãø ±â°£ µ¿¾È ½Å°æ Àåºñ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î World Population Ageing 2021 º¸°í¼¿¡ µû¸£¸é ¸ß½ÃÄÚÀÇ 65¼¼ ÀÌ»ó Àα¸´Â 2030³â±îÁö 931¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ¿Í °°ÀÌ ³ëÀÎ Àα¸ Áõ°¡´Â ½Å°æÁúȯÀÇ ¹ßº´ÀÌ ½¬¿öÁö°í Áø´Ü ¹× Ä¡·á¸¦ À§ÇÑ ´Ù¾çÇÑ ½Å°æ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
¶ÇÇÑ ÀÌ Áö¿ª¿¡¼ ½Å°æ±â±â¸¦ °³¹ßÇÏ´Â ±â¾÷ÀÇ ³ë·ÂÀÌ È°¹ßÇØÁö°í ÀÖ´Â °Íµµ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î(2021³â) 1¿ù, ¹Ì±¹ ½ÄǰÀǾ౹Àº ClearMind Biomedical»çÀÇ ½Å°æ³»½Ã°æ 'Axonpen System'¿¡ Çã°¡¸¦ ÁÖ¾ú½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº µÎ°³ ³» Á¶Á÷°ú ü¾×À» ºñÃß¾î ½Ã°¢ÈÇϰųª ¼ö¼ú Áß ÅëÁ¦ µÈ Á¶Á÷°ú ü¾×À» ÈíÀÔÇÏ´Â µ¥ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
µû¶ó¼ ½Å°æÁúȯ À¯º´·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, ÀÌ Áö¿ªÀÇ ±â¾÷ Ȱµ¿ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½ÃÀå ÁøÃâ±â¾÷ Áß ÀϺδ ȯÀÚ¿¡°Ô Æí¸®ÇÑ Àúħ½À óġ¸¦ ¼ö¹ÝÇϴ ÷´Ü ½Ã¹Ä·¹À̼ǰú ½Å°æÁ¶Àý ±â¼ú °³¹ßÀ» À§ÇÑ ¿¬±¸ °³¹ß¿¡ Á¾»çÇϰí ÀÖ´Â ±â¾÷µµ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸¹Àº ºñ°ø°³ ±â¾÷µéÀÌ ¸·´ëÇÑ ÀÌÀÍÀ» ¾ò±â À§ÇØ »õ·Î¿î ½Å°æ Àåºñ °³¹ß¿¡ Å« °ü½ÉÀ» º¸À̰í ÀÖ½À´Ï´Ù. ½Å°æ Àåºñ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â B. Braun Melsungen AG, Boston Scientific Corporation, Stryker Corporation, Medtronic PLC, Abbott Laboratories, Smith & Nephew µîÀÌ ÀÖ½À´Ï´Ù.
The Global Neurology Devices Market size is estimated at USD 14.40 billion in 2024, and is expected to reach USD 18.26 billion by 2029, growing at a CAGR of 4.86% during the forecast period (2024-2029).
The COVID-19 pandemic had a significant impact on the global healthcare systems, with significant consequences not only for COVID-19-infected patients but also for others, resulting in the cancellation of treatment and surgical procedures to manage and reserve resources. For instance, in June 2020, the World Health Organization issued the results of a survey conducted by 155 countries for three weeks in May 2020, which showed that the prevention and treatment services of various chronic diseases, including various neurodegenerative disorders, such as Parkinson's, Alzheimer, and dementia, had been severely disrupted, and this has become a significant concern because people living with chronic diseases are at higher risk of severe COVID-19-related illness and death. In addition, 53% of the countries reported partial or complete disruption of services. This disruption in the management of different neurological conditions has impacted the lives of the patients. Moreover, the pandemic can also have a negative impact on new product launches, which are estimated to be the most prominent factor in the growth of the market studied. For instance, in April 2020, Biogen delayed Alzheimer's and dementia drug filing to Food and Drug Administration (FDA) while citing the complexity of data analysis and the impact of COVID-19 on its R&D resources. With the resumed services, treatment and surgical procedures and increased hospital visits are likely to increase the demand for neurology devices and treatment for various neurological disorders, thereby impacting the market growth.
The factors propelling the growth of the market are an increase in the incidence of neurological disorders, huge investments by private players in neurology devices, increase in research and development in the field of Neurotherapy.
The increasing burden of neurological disorders among the population is the key factor driving the demand for neurology devices over the forecast period. For instance, according to data published by the United Nations, in February 2021, about 1 billion people, nearly one in six of the world's population, suffer from neurological disorders, such as Alzheimer's and Parkinson's disease, strokes, multiple sclerosis, epilepsy migraine, brain injuries, and neuro infections in 2020. Additionally, as per the same source 62 million suffered from cerebrovascular disease, 50 million people suffered from epilepsy, 326 million from migraine, and 24 million from Alzheimer's disease and other dementias in 2019. Thus, the rising prevalence of neurological disorders among the population is expected to increase the demand for neurology devices to restore hearing and sight and provide an increased function for limb loss or congenital limb differences, thereby expected to augment the market growth.
Furthermore, the rising awareness among the population about neurological diseases and their treatment options is expected to drive market growth. For instance, as per a report published by World Health Organization (WHO), in April 2022, titled 'Draft Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022-2031' 100% of countries are expected to have at least one functioning awareness campaign or advocacy program for neurological disorders by 2031. Such initiatives by the renowned organization are expected to drive the market in the coming future.
However, the high cost of equipment and stringent Food and Drug Administration validation and guidelines for new devices are likely to restrain the growth of the market.
The neurostimulation devices segment is expected to witness significant growth over the forecast period owing to the factors such as the increasing prevalence of neurological disorders coupled with an increase in the aging population and lifestyle-related disorders such as depression and chronic pain and increasing adoption of technologically advanced products.
In addition, according to a study published by IEEE Engineering in Medicine and Biology Society, in February 2021, titled "New Advances in Neurostimulation for Chronic Pain", it has been found that Mainstay Medical designed a ReActiv8 implantable restorative neurostimulation system, which is used to treat intractable chronic lower back pain. Thus, the increasing advances in the products are expected to rise the adoption of these devices, thereby propelling the market growth.
Moreover, the increasing product launches and technological advancements in pain management are expected to increase the demand for neurostimulation devices, thereby fueling market growth. For instance, In July 2021, Medtronic launched the Percept PC Deep Brain Stimulation (DBS) system. The system integrated with BrainSense technology is made to administer therapeutic stimulation both inside and outside of the clinic while simultaneously capturing brain signals. The Percept PC device is indicated for individuals with Parkinson's disease, tremor, dystonia, and epilepsy and provides enhanced comfort.
Thus, rising product advancements and increasing product launches are expected to increase the demand for the studied segment, thereby boosting the market growth.
North America is expected to have a significant major market share in the neurology devices market owing to the factors such as the rising prevalence of neurological disorders, increasing funding from various organizations regarding the development for the treatment of neurodegenerative diseases, and rising research and development activities in the region.
The increasing burden of neurological disorders such as Parkinson's diseases, Alzheimer's diseases, epilepsy, neuromuscular disorders, and others is the key factor driving the growth of the market. For instance, according to data from Alzheimers.org, 6.2 million Americans aged 65 and older were thought to have Alzheimer's-related dementia in the United States in 2021. Also, the Parkinson's Foundation estimated that nearly 1 million Americans were living with Parkinson's disease (PD) in 2020. As per the same source, nearly 60,000 Americans are diagnosed with Parkinson's disease every year. Similarly, as per the Government of Canada Statistics report, as of July 2021, around 18.5% of the Canadian population was aged above 65 years which is an increase from 17.5% in July 2020. Thus, the rising burden of neurological diseases among the population is expected to increase the demand for early diagnosis and treatment, further increasing the demand for neurology devices, thereby propelling the market growth.
In addition, the growing geriatric population and the presence of robust healthcare infrastructure for neurological diagnostics and treatment are also contributing to the growth of the neurology devices market over the forecast period. For instance, according to the World Population Ageing 2021 report, the Mexican population aged 65 years and older is projected to reach 9.31 million by 2030. Thus, the increasing aging population is more prone to develop neurological disorders which are expected to increase the demand for various neurology devices for diagnosing and treatment of the conditions, which is expected to fuel the market growth.
Moreover, the rising company initiatives to develop neurology devices in the region are also contributing to the growth of the market. For instance, in January 2021, the United States Food and Drug Administration granted clearance to ClearMind Biomedical's neuro endoscope, the Axonpen System. This system can be used to illuminate and visualize intracranial tissue and fluids as well as the controlled tissue and/or fluid aspiration during surgery.
Thus, the increasing prevalence of neurological disorders, growing geriatric population, and increasing company activities in the region are expected to augment the market growth over the forecast period.
There are market participants involved in research and development for the development of advanced simulation and neuromodulation techniques with minimally invasive procedures that are preferable to the patients. Furthermore, many private companies are showing great interest in developing novel neurological devices to earn huge profits. Some of the key players in the neurology devices market are B. Braun Melsungen AG, Boston Scientific Corporation, Stryker Corporation, Medtronic PLC, Abbott Laboratories, and Smith & Nephew.